Compare MDXH & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDXH | ANIK |
|---|---|---|
| Founded | 2003 | 1983 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.4M | 192.4M |
| IPO Year | 2021 | 1996 |
| Metric | MDXH | ANIK |
|---|---|---|
| Price | $3.31 | $14.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $7.67 | ★ $17.00 |
| AVG Volume (30 Days) | 112.8K | ★ 130.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $112,819,000.00 |
| Revenue This Year | $30.31 | $5.98 |
| Revenue Next Year | $18.38 | $7.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.36 | $7.90 |
| 52 Week High | $5.33 | $17.14 |
| Indicator | MDXH | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 43.21 | 85.18 |
| Support Level | $3.05 | $9.36 |
| Resistance Level | $3.78 | N/A |
| Average True Range (ATR) | 0.18 | 0.67 |
| MACD | -0.02 | 0.30 |
| Stochastic Oscillator | 17.92 | 99.57 |
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.